Skip to main content

Merck KGaA, Millipore, PT Peptide Technologies

Germany's Merck KGaA to Use Cenix's RNAi Service to Screen for Drugs
Cenix BioScience this week said German drug maker Merck KGaA will use Cenix’s RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
Financial terms of the deal were not disclosed.

Millipore to Market JPT Peptide's Enzyme Profiling Products
Millipore this week said that it will market and distribute JPT Peptide Technologies’ line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases, and proteases.
JPT is a wholly owned subsidiary of Berlin-based Jerini. The non-exclusive deal is worldwide.
JPT's products “strongly complement our existing portfolio of cell signaling reagents and services,” Rick Ryan, vice president of the drug discovery business unit for the bioscience division of Millipore, said in a statement.
Financial terms of the deal were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.